Pulse oral corticosteroids in pediatric chronic inflammatory demyelinating polyneuropathy

Amanda B. Rogers, Craig M. Zaidman, Anne M. Connolly

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Childhood onset chronic inflammatory demyelinating polyneuropathy (CIDP) often requires long-term immunomodulatory therapy. We report a comprehensive review of our treatment of pediatric CIDP with a focus on high-dose weekly corticosteroids (“pulse oral corticosteroids”), a treatment method that is not commonly reported. We retrospectively reviewed medical records of pediatric patients with CIDP treated at our center between 2000 and 2018 for whom we had at least 12 mo follow-up. Here, we describe the demographics, disease course, treatment regimens, and long-term outcomes of these patients. Twenty-five patients were identified for analysis. Pulse oral corticosteroid monotherapy was the predominant maintenance treatment in 56% of patients. Patients were followed for a median of 4 y. Side effects were seen in a minority of patients. The probability of a normal exam or being off treatment at last follow-up was similar regardless of predominant maintenance therapy. Pulse oral corticosteroid therapy is a safe and effective long-term treatment option in children with CIDP.

Original languageEnglish
Pages (from-to)705-709
Number of pages5
JournalMuscle and Nerve
Issue number6
StatePublished - Dec 2020


  • CIDP
  • corticosteroids
  • immunomodulatory therapy
  • inflammatory neuropathy
  • pediatric CIDP


Dive into the research topics of 'Pulse oral corticosteroids in pediatric chronic inflammatory demyelinating polyneuropathy'. Together they form a unique fingerprint.

Cite this